Search

Your search keyword '"Delaloge S"' showing total 1,112 results

Search Constraints

Start Over You searched for: Author "Delaloge S" Remove constraint Author: "Delaloge S"
1,112 results on '"Delaloge S"'

Search Results

2. Real-world effectiveness of post-trastuzumab emtansine treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer: a multicenter, matched cohort analysis from the Epidemiology Strategy and Medical Economics database (2008-2018)

5. Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review

6. ESMO Guidance for Reporting Oncology real-World evidence (GROW)

7. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023

11. Opérer ou non une lésion atypique du sein ? Prise en compte de l’anxiété dans l’aide à la décision partagée à partir d’une cohorte prospective de 300 patientes

12. P23 - Evolution des traitements de première ligne et survie en vie réelle des femmes âgées atteintes d'un cancer du sein métastatique RH+/HER2- par rapport aux femmes plus jeunes : résultats de l’étude observationnelle et nationale ESME

13. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

14. Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort

15. Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program

17. Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis

18. T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants

20. Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial

22. ESMO Guidance for Reporting Oncology real-World evidence (GROW)

25. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study

27. A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)

28. Traitement de première ligne et survie en vie réelle des femmes âgées atteintes d'un cancer du sein métastatique RH+/HER2- par rapport aux femmes plus jeunes : résultats de l’étude observationnelle et nationale ESME

29. 193MO Development of a deep learning model using a large real-world database to predict overall survival in patients with metastatic breast cancer (MBC)

31. 203P Clinical effectiveness of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer (mBC) by ER expression level: Subgroup analysis from phase IIIb LUCY trial

35. 131P Efficacy of neoadjuvant letrozole and palbociclib in HER2-low vs HER2 zero luminal breast cancer: An analysis of the Unicancer Neopal phase II study

37. Comprehensive mapping review of real-world evidence publications focusing on targeted therapies in solid tumors : A collaborative work from ESMO real-world data and Digital Health Working Group

38. Real-world evidence contributions to European medicines agency's safety and efficacy evaluations of oncology targeted therapies between 2018-2022

39. ESMO Guidance for Reporting Oncology real-World evidence (GROW)

40. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study

41. Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program

45. Deep Learning Allows Assessment of Risk of Metastatic Relapse from Invasive Breast Cancer Histological Slides

47. 212MO AMEERA-3, a phase II study of amcenestrant (AMC) versus endocrine treatment of physician’s choice (TPC) in patients (pts) with endocrine-resistant ER+/HER2− advanced breast cancer (aBC)

Catalog

Books, media, physical & digital resources